Compare THFF & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THFF | ANNX |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.9M | 873.3M |
| IPO Year | 1995 | 2020 |
| Metric | THFF | ANNX |
|---|---|---|
| Price | $74.71 | $4.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $62.00 | $16.50 |
| AVG Volume (30 Days) | 91.2K | ★ 2.8M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 67.00 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $4.03 | $16,320.74 |
| P/E Ratio | $20.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.21 | $2.54 |
| 52 Week High | $84.17 | $7.18 |
| Indicator | THFF | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 32.39 | 45.25 |
| Support Level | $64.54 | $3.79 |
| Resistance Level | $75.61 | $4.36 |
| Average True Range (ATR) | 1.58 | 0.24 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 2.39 | 77.61 |
First Financial Corp operates as a financial holding company, which is engaged in the provision of financial services in the United States. The company offers a wide variety of financial services including commercial, mortgage, and consumer lending, lease financing, trust account services, depositor services and insurance services, through its subsidiaries. Its primary source of revenue is derived from loans to customers and investment activities. Company's loan portfolio was diversified in Commercial, Residential and consumer domains.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.